Just who is the neuroscientist and university professor AstraZeneca has nominated to its board of directors? A sometime critic of the pharma industry, the Financial Times points out.
AstraZeneca's respiratory aspirations just took a hit. While it guns for a lead in the field, it may have to do so without much help from asthma med Pulmicort, which lost a patent in U.S. federal court Friday.
Looking to tie its two big R&D hubs in Cambridge, U.K., and Gothenburg, Sweden, closer together, AstraZeneca has struck a deal to reserve 20 seats on a Sun Air flight that will make a round-trip journey each day from Monday through Thursday.
The moment of truth is arriving for AstraZeneca's anti-infectives unit. For more than a year now, the pharma giant has been quietly shopping a deal, seeking an investor willing to take control of the assets, while allowing AstraZeneca to keep a substantial stake for itself, FierceBiotech has learned. Now, industry insiders are buzzing that the company is coming down to the wire on a final decision--and that throughout the negotiations, staffers have been steadily fleeing the once-sizable operation.
The U.S. Justice Department has slapped AstraZeneca for an alleged kickback scheme. The $7.9 million penalty is peanuts compared with Big Pharma's other marketing settlements--in fact, AstraZeneca's own settlement topped $500 million.
Alzheimer's, depression, Parkinson's and the rest of the neuroscience targets of interest in biopharma have created a disaster zone for R&D teams in recent years. That's why AstraZeneca, GlaxoSmithKline and others have either pulled way back or completely out of the field. But in their wake, you can now detect a new generation of small biotechs stepping up with promising programs to revolutionize the field.
A 13% jump in the number of compounds in development at AstraZeneca has seen it leapfrog Pfizer ($PFE) to claim fourth place on Citeline's list of the biggest development pipelines. The switch means European Big Pharma companies occupy the top four spots, with GlaxoSmithKline, Novartis and Roche taking the podium positions.
Good news for Teva when it comes to Mylan's generic version of AstraZeneca's Nexium: It won't be around for a little while.
AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal.
AstraZeneca's R&D blueprint for 2015 calls for hunkering down on its core pipeline assets and taking a cue from the startup world with the rest, CEO Pascal Soriot said, planning to partner up in hopes of maximizing value.